

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Application No.	10/802,970
	Filing Date	March 16, 2004
	First Named Inventor	Carl-Magnus Andersson
	Art Unit	1624
(Multiple sheets used when necessary)	Examiner	Jason H. Johnsen
SHEET 1 OF 1	Attorney Docket No.	ACADIA.014C2

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
/J.M./	1	Notice of Allowability dated March 5, 2007, from Application No. 10/601,070 filed June 20, 2003	
/J.M./	2	Notice of Allowability dated June 19, 2007, from Application No. 11/418,322 filed May 3, 2006	

4106303-akr  
080707

Examiner Signature	/John Mabry/ (01/18/2008)	Date Considered
--------------------	---------------------------	-----------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Application No.	10/802,970
	Filing Date	March 16, 2004
	First Named Inventor	Carl-Magnus Andersson
	Art Unit	1624
(Multiple sheets used when necessary)	Examiner	Jason H Johnsen
SHEET 1 OF 1	Attorney Docket No.	ACADIA.014C2

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
/J.M./	1	Office Action dated April 6, 2007, from Application No. 11/418,322 filed May 3, 2006.	
/J.M./	2	Office Action dated May 8, 2007, from Application No. 11/417,866 filed May 3, 2006.	

3800447  
052307

Examiner Signature	/John Mabry/ (01/18/2008)	Date Considered
<p><b>*Examiner:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>		

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Application No.	10/802,970
	Filing Date	March 16, 2004
	First Named Inventor	Carl-Magnus Andersson
	Art Unit	1624
(Multiple sheets used when necessary)	Examiner	Jason H Johnsen
SHEET 1 OF 1	Attorney Docket No.	ACADIA.014C2

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>
/J.M./	1	HU 157325	03-19-1998	Rudolf, et al.		
/J.M./	2	WO04/039322 A2	05-13-2004	Micro, Inc.		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
/J.M./	3	ALVISI, N. 1892. Sulla formazione di derivati pirazolici dalle dicloridrine e dalla tribromidrina della glicerina ordinaria, <i>Gazz. Chem. Ital.</i> 22:158-168.	
/J.M./	4	ARCHIBALD, et al., 1974 "Benzamidopiperdines. 2. Heterocyclic Compounds Related to Indoramin" <i>J. Medicinal Chemistry</i> , 17(7):736-739.	
/J.M./	5	ARCHIBALD, et al., 1974 "Benzamidopiperdines. 3. Heterocyclic Compounds Related to Indoramin" <i>J. Medicinal Chemistry</i> , 17(7):739-744	
/J.M./	6	ARCHIBALD, et al., 1974 "1,4-Bis-(2-indol-3-ylethyl)piperdines" <i>J. Medicinal Chemistry</i> , 17(7):745-747	
/J.M./	7	BASSUS, et al. 1974. Psychotropes potentiels. X. Synthèse de butyrophénones à cycle pipéridine-spiro-tétrahydrooxazinone douées d'activité neuroleptique. <i>Eur. J. Med. Chem. - Chimica Therapeutica</i> , 9(4):416-423.	
/J.M./	8	IRIKURA et al., 1971 "New Anticulcer Agents. 1. Synthesis and Biological Activities of 1-Acyl-2-, -3-, -4-substituted Benzamidopiperdines" <i>J. Medicinal Chemistry</i> 14(4): 357-361.	
/J.M./	9	FINAR, et al. 1954. The preparation and properties of some derivatives of 1-phenylpyrazole, <i>J. Chem. Soc.</i> , pp. 2293-2298.	
/J.M./	10	OLÁH, et al. 1956. Notiz über die N-formylierung von aminen mit formylfluorid. <i>Chem. Ber.</i> , 89:2211-2212.	
/J.M./	11	STEFANCICH, et al. 1984. Agenti antiinfiammatori non-steroidi: Nota III - sintesi ed attività analgesica-antiinfiammatoria di 4-(pirrol-1-il)-fenilacetamidi e di 4-(pirrol-1-il)fenetilamine. <i>Farmaco Ed. Sci.</i> , 39(9):752-764.	
/J.M./	12	TOLSTIKOV et al. 1991 "Synthesis and Reactivity of N-substituted aminoamides, antiarrhythmic and local anaesthetic activity" <i>Russian Chemical Reviews</i> 60(4):420434.	
/J.M./	13	WOLF, V. V. 1952. Über alkin-amine I. Aryl-propargyl-amine. <i>Liebigs Ann. Chem.</i> , 576:35-45.	
/J.M./	14	International Preliminary Report on Patentability dated March 27, 2007, for PCT/US2005/034813.	
/J.M./	15	International Preliminary Report on Patentability dated March 27, 2007, for PCT/US2005/034376.	

3585083  
032807

Examiner Signature	/John Mabry/ (01/18/2008)	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Application No.	10/802,970
	Filing Date	March 16, 2004
	First Named Inventor	Carl-Magnus Andersson
	Art Unit	1624
(Multiple sheets used when necessary)	Examiner	Jason H Johnsen
SHEET 1 OF 8	Attorney Docket No.	ACADIA.014C2

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
/J.M./	1	4,138,492	02-06-1979	Noverola, et al.	
	2	5,025,013	06-18-1991	Barreau, et al.	
	3	5,214,055	05-25-1993	Peglion, et al.	
	4	5,461,066	10-24-1995	Gericke, et al.	
	5	5,621,010	04-15-1997	Sueda, et al.	
	6	5,795,894	08-18-1998	Shue, et al.	
	7	5,869,488	02-09-1999	Shue, et al.	
	8	5,912,132	06-15-1999	Brann	
	9	5,955,281	09-21-1999	Brann	
	10	6,107,324	08-22-2000	Behan, et al.	
	11	6,140,509	10-31-2000	Behan, et al.	
	12	6,150,393	11-21-2000	Behan, et al.	
/J.M./	13	6,358,698	03-19-2002	Weiner, et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>
/J.M./	14	CA 984843	03-02-1976	John Wyeth & Brother Limited		
	15	EP 0 005 318 A1	11-14-1979	Janssen Pharm.		
	16	EP 0 379 441 A1	07-25-1990	Rhone-Poulenc Sante		
	17	EP 0 548 015 A1	06-23-1993	Ciba-Geigy AG		
	18	WO 97/08166 A1	03-06-1997	Schering Corporation		
	19	WO 97/11940 A1	04-03-1997	Eli Lilly and Company		
	20	WO 98/11128 A1	03-19-1998	Dr. Karl Thomae GMBH		
	21	WO 98/17646 A1	04-30-1998	Dr. Karl Thomae GMBH		
	22	WO 99/52927 A1	10-21-1999	Arena Pharmaceuticals, Inc.		
	23	WO 00/56335 A1	09-28-2000	The Regents of the University of California		
	24	WO 00/69810 A1	11-23-2000	Novo Nordisk A/S		
/J.M./	25	WO 03/070246 A1	08-28-2003	Pfizer Products Inc.		

Examiner Signature /John Mabry/ (01/18/2008)	Date Considered
--	-----------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Application No.	10/802,970
	Filing Date	March 16, 2004
	First Named Inventor	Carl-Magnus Andersson
	Art Unit	1624
(Multiple sheets used when necessary)	Examiner	Jason H Johnsen
SHEET 2 OF 8	Attorney Docket No.	ACADIA.014C2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
/J.M./	26	ADAM, et al. 1989. Effects of repeated ritanserin on middle-aged poor sleepers. <i>Psychopharmacology</i> , 99:219-221.	
	27	ADELL, et al. 2005. Strategies for producing faster acting antidepressants. <i>Drug Discovery Today</i> , 10(8):578-585.	
	28	AKIN, et al. 2004. Decreased serotonin 5-HT <sub>2A</sub> receptor-stimulated phosphoinositide signaling in fibroblasts from melancholic depressed patients. <i>Neuropsychopharmacology</i> , 29:2081-2087.	
	29	ALVISI, N. 1892. Sulla formazione di derivati pirazolici dalle dicloridrine e dalla tribromidrina della glicerina ordinaria, <i>Gazz. Chem. Ital.</i> 22:158-168.	
	30	ANTILLA, et al. 2001. Copper-catalyzed coupling of arylboronic acids and amines. <i>Organic Letters</i> , 3(13):2077-2079.	
	31	ANTILLA, et al. 2002. The copper-catalyzed <i>N</i> -arylation of indoles. <i>J. Am. Chem. Soc.</i> , 124:11684-11688.	
	32	ARTICO, et al. 1992. Aromatic hydrazides as specific inhibitors of bovine serum amine oxidase. <i>Eur. J. Med. Chem.</i> , 27:219-228.	
	33	BARCHAS, J. 1973. <i>Serotonin and Behavior</i> . New York: Academic Press.	
	34	BASSUS, et al. 1974. Psychotropes potentiels. X. Synthèse de butyrophénones à cycle pipéridine-spiro-tétrahydrooxazinone douées d'activité neuroleptique. <i>Eur. J. Med. Chem. - Chimica Therapeutica</i> , 9(4):416-423.	
	35	BENNETT, et al. 1993. Suppression of dyskinesias in advanced Parkinson's disease. II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms. <i>Neurology</i> , 43:1551-1555.	
	36	BHATIA, et al. 1998. 5-Lipoxygenase inhibitors: Synthesis and structure-activity relationships of a series of 1-Aryl-2H,4H-tetrahydro-1,2,4-triazin-3-ones. <i>J. Med. Chem.</i> , 39:3938-3950.	
	37	BIAGI, et al. 1988. 1,2,3-Triazoles: Structural changes on two effective inhibitors of the prostaglandin synthesis <i>in vitro</i> . <i>Farmaco Ed. Sci.</i> , 43:597-612.	
	38	BIBBIANI, et al. 2001. Serotonin 5-HT <sub>1A</sub> agonist improves motor complications in rodent and primate parkinsonian models. <i>Neurology</i> , 57:1829-1834.	
	39	BIRKMAYER, et al. 1974. Nucleus ruber and L-Dopa psychosis: Biochemical post-mortem findings. <i>Journal of Neural Transmission</i> , 35:93-116.	
	40	BLAKLEY, et al. 2001. Bidirectional changes in ethanol consumption in rats with site-specific antisense down-regulation of 5-hydroxytryptamine <sub>2A</sub> receptors in brain. <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 299(1):277-289.	
	41	BLIER, et al. 2001. Putative mechanisms of action of antidepressant drugs in affective and anxiety disorders and pain. <i>Journal of Psychiatry &amp; Neuroscience</i> , 26(1):37-43.	
/J.M./	42	BLIER, et al. 2005. Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. <i>J. Clin. Psychiatry</i> , 66(suppl 8):30-40.	

Examiner Signature	/John Mabry/ (01/18/2008)	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>		

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Application No.	10/802,970
	Filing Date	March 18, 2004
	First Named Inventor	Carl-Magnus Andersson
	Art Unit	1624
(Multiple sheets used when necessary)	Examiner	Jason H Johnsen
SHEET 3 OF 8	Attorney Docket No.	ACADIA.014C2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
/J.M./	43	BROWN, et al. 1924. Catalytic alkylation of aniline, <i>J. Am. Chem. Soc.</i> , 46(8):1836-1839.	
	44	BÜCHI, et al. 1969. Synthesis of (±)-nuciferal. <i>J. Org. Chem.</i> , 34(4):1122-1123.	
	45	BUTCHER, et al. 1970. L-Dopa induced changes in central monoamine neurons after peripheral decarboxylase inhibition. <i>Letters to the Editor, J. Pharm. Pharmac.</i> , 22:313-316.	
	46	BUU-HÖI, et al. 1951. Further studies in the alkylation of phenols and thiophenols, <i>J. Org. Chem.</i> , 16:988-994.	
	47	CACCHI, et al. 2003. Palladium-catalyzed reaction of aryl iodides with acetic anhydride. A carbon monoxide-free synthesis of acetophenones. <i>Organic Letters</i> , 5(3):289-291.	
	48	CARMAN, et al. 1998. A further synthesis of an analogue of the antifungal/antiherbivore lipid from avocado. <i>Aust. J. Chem.</i> , 51:955-959.	
	49	CATARZI, et al. 2001. Synthesis, ionotropic glutamate receptor binding affinity, and structure-activity relationships of a new set of 4,5-dihydro-8-heteroaryl-4-oxo-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylates analogues of TQX-173. <i>J. Med. Chem.</i> , 44:3157-3165.	
	50	Chemical Abstracts, 128:111548. BRANN, M. R. 1998. Identification of ligands by selective amplification of cells transfected with receptors and marker enzymes.	
	51	CLARK et al. 1983. Antihypertensive 9-substituted 1-Oxa-4,9-diazaspiro[5.5]undecan-3-ones. <i>J. Med. Chem.</i> , 26:855-861.	
	52	DeCLERCK, et al. 1987. Increase in slow-wave sleep in humans with the serotonin-S <sub>2</sub> antagonist ritanserlin. <i>Current Therapeutic Research</i> , 41(4):427-432.	
	53	DUNN, et al. 1986. Analgetic and antiinflammatory 7-arylbenzofuran-5-ylacetic acids and 7-arylbenzothiophene-5-ylacetic acids. <i>J. Med. Chem.</i> , 29:2326-2329.	
	54	DURIF, et al. 1997. Low-dose clozapine improves dyskinesias in Parkinson's disease. <i>Neurology</i> , 48:658-662.	
	55	EMERSON, et al. 1938. The reductive alkylation of aniline. <i>J. Am. Chem. Soc.</i> , 60:2023-2025.	
	56	ERMAKOV, et al. 1981. Use of Mass spectrometry in structural and stereochemical studies. <i>Chemistry of Heterocyclic Compounds</i> , 1:72-77.	
	57	EVERETT, et al. 1970. L-Dopa: Effect on concentrations of dopamine, norepinephrine, and serotonin in brains of mice. <i>Science</i> , 168:849-850.	
	58	FINAR, et al. 1954. The preparation and properties of some derivatives of 1-phenylpyrazole, <i>J. Chem. Soc.</i> , pp. 2293-2298.	
	59	FISERA, et al. 1994. Synthesis of spiro-substituted 1,3-oxazines by a new sequence leading to spiroheterocycles. <i>Monatshefte für Chemie</i> , 125:909-919.	
/J.M./	60	FRIEDMAN, et al. 1999. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. <i>N. Engl. J. Med.</i> , 340(10):757-763.	

Examiner Signature     /John Mabry/ (01/18/2008)	Date Considered
--	-----------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Application No.	10/802,970
	Filing Date	March 16, 2004
	First Named Inventor	Carl-Magnus Andersson
	Art Unit	1624
(Multiple sheets used when necessary)	Examiner	Jason H Johnsen
SHEET 4 OF 8	Attorney Docket No.	ACADIA.014C2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
/J.M./	61	FRIEDMAN, et al. 2000. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. <i>Movement Disorders</i> , 15(2):201-211.	
	62	GAINETDINOV, et al. 2001. Genetic animal models: Focus on schizophrenia. <i>Trends in Neurosciences</i> , 24(9):527-533.	
	63	GAMMA, et al. 2000. 3,4-Methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by [ <sup>15</sup> O]-PET in healthy humans. <i>Neuropsychopharmacology</i> , 23(4):388-395.	
	64	GAWLEY, R. E., & Aubé, J. 1996. <i>Principles of Asymmetric Synthesis</i> . New York: Pergamon.	
	65	GILLMAN, P. K. 2005. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. <i>British Journal of Anaesthesia</i> , 95(4):434-441.	
	66	GOOßEN, et al. 2001. Palladium-catalyzed synthesis of aryl ketones from boronic acids and carboxylic acids or anhydrides. <i>Angew. Chem. Int. Ed.</i> , 40:3458-3460.	
	67	GSTACH, et al. 1990. Rearrangement of 3,3-disubstituted 1-aryl-4,5-dihydro-5-oxo-3H-1,2,4-triazolium tetrafluoroborates; Part 1. A versatile synthesis of 1,5-disubstituted 2-aryl-1,2-dihydro-3H-1,2,4-triazol-3-one tetrafluoroborates. <i>Synthesis</i> , pp. 803-808.	
	68	GUTHRIE, et al. 1993. The tetrahedral intermediate from the hydration of N-methylformanilide. <i>Can. J. Chem.</i> , 71:2109-2122.	
	69	HARTWIG, J. F. 1998. Transition metal catalyzed synthesis of arylamines and aryl ethers from aryl halides and triflates: Scope and mechanism. <i>Angew. Chem. Int. Ed.</i> , 37:2047-2067.	
	70	HICKINBOTTOM, W. J. 1930. The preparation of secondary alkylaryl-amines and their purification. <i>J. Chem. Soc.</i> , pp. 992-994.	
	71	HIRST, et al. 1895. A method for preparing the formyl derivatives of the aromatic amines. <i>J. Chem. Soc.</i> , 67:829-831.	
	72	IDZIKOWSKI, et al. 1991. A dose response study examining the effects of ritanserin on human slow wave sleep. <i>Br. J. Clin. Pharmacol.</i> , 31:193-196.	
	73	JAEGER, et al. 1941. Two ketones of the stilboestrol group. <i>J. Chem. Soc.</i> , 744-747.	
	74	KANAYAMA, et al. 2005. New treatment of lumbar disc herniation involving 5-hydroxytryptamine <sub>2A</sub> receptor inhibitor: A randomized controlled trial. <i>J. Neurosurg: Spine</i> , 2:441-446.	
	75	KLAPARS, et al. 2001. A general and efficient copper catalyst for the amidation of aryl halides and the N-arylation of nitrogen heterocycles. <i>J. Am. Chem. Soc.</i> , 123:7727-7729.	
	76	KLAPARS, et al. 2002. A general and efficient copper catalyst for the amidation of aryl halides. <i>J. Am. Chem. Soc.</i> , 124:7421-7428.	
	77	KWONG, et al. 2002(a). Copper-catalyzed coupling of alkylamines and aryl iodides: An efficient system even in an air atmosphere. <i>Organic Letters</i> , 4(4):581-584.	
/J.M./	78	KWONG, et al. 2002(b). A general, efficient, and inexpensive catalyst system for the coupling of aryl iodides and thiols. <i>Organic Letters</i> , 4(20):3517-3520.	

Examiner Signature	/John Mabry/ (01/18/2008)	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>		

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Application No.	10/802,970	
	Filing Date	March 16, 2004	
	First Named Inventor	Carl-Magnus Andersson	
	Art Unit	1624	
(Multiple sheets used when necessary)		Examiner	Jason H Johnsen
SHEET 5 OF 8		Attorney Docket No.	ACADIA.014C2

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
/J.M./	79	KWONG, et al. 2003. Mild and efficient copper-catalyzed amination of aryl bromides and primary alkylamines. <i>Organic Letters</i> , 5(6):793-796.	
	80	LANDINI, et al. 1974. A convenient synthesis of primary and secondary dialkyl and aryl alkyl sulfides in the presence of phase-transfer catalysts. <i>Synthesis</i> , pp. 565-566.	
	81	LANDOLT, et al. 1999. Serotonin-2 receptors and human sleep: Effect of a selective antagonist on EEG power spectra. <i>Neuropsychopharmacology</i> , 21(3):455-466.	
	82	LEYSEN, et al. 1978. Serotonergic component of neuroleptic receptors. <i>Nature</i> , 272:168-171.	
	83	LI, G. Y. 2002. Highly active, air-stable palladium catalysts for the C-C and C-S bond-forming reactions of vinyl and aryl chlorides: Use of commercially available [(t-Bu) <sub>2</sub> P(OH)] <sub>2</sub> PdCl <sub>2</sub> , [(t-Bu) <sub>2</sub> P(OH)PdCl <sub>2</sub> ], and [(t-Bu) <sub>2</sub> PO . . H . . OP(t-Bu) <sub>2</sub> ]PdCl <sub>2</sub> as catalysts. <i>J. Org. Chem.</i> , 67:3643-3650.	
	84	LIECHTI, et al. 2001. Effects of MDMA (ecstasy) on prepulse inhibition and habituation of startle in humans after pretreatment with Citalopram, Haloperidol, or Ketanserin. <i>Neuropsychopharmacology</i> , 24(3):240-252.	
	85	MAREK, et al. 2003. Synergistic action of 5-HT <sub>2A</sub> antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. <i>Neuropsychopharmacology</i> , 28:402-412.	
	86	MAREK, et al. 2005. The selective 5-HT <sub>2A</sub> receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine. <i>Neuropsychopharmacology</i> , 30:2205-2215.	
	87	MAVUNKEL, et al. 1996. Synthesis and characterization of pseudopeptide bradykinin B2 receptor antagonists containing the 1,3,8-triazaspiro[4.5]decan-4-one ring system. <i>J. Med. Chem.</i> , 39:3169-3173.	
	88	MAYER, et al. 2003. Ritanserin improves sleep quality in narcolepsy. <i>Pharmacopsychiatry</i> , 364:150-155.	
	89	MELTZER, et al. 1995. Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson's disease. <i>Neuropsychopharmacology</i> , 12(1):39-45.	
	90	MENG, et al. 1991. Synthetic approaches toward glidobamine, the core structure of the glidobactin antibiotics. <i>Tetrahedron</i> , 47(32):62510-6264.	
	91	MICÓVIĆ, et al. 1991. A simple method for preparation of secondary aromatic amines. <i>Synthesis</i> , 11:1043-1045.	
	92	MIYATA, et al. 2000. Sarpogrelate, a selective 5-HT <sub>2A</sub> serotonergic receptor antagonist, inhibits serotonin-induced coronary artery spasm in a porcine model. <i>Journal of Cardiovascular Pharmacology</i> , 35(2) 294-301.	
	93	MOULIGNIER, A. 1994. Récepteurs centraux de la sérotonine principaux aspects fondamentaux et fonctionnels application thérapeutiques. <i>Rev. Neurol.</i> , 150:3-15.	
	94	MOULIGNIER, A. 1994. Récepteurs centraux de la sérotonine principaux aspects fondamentaux et fonctionnels application thérapeutiques. <i>Rev. Neurol.</i> , 150:3-15.	✓ (Abstract)
/J.M./	95	MOUNÉ, et al. 1997. Total synthesis of dolatrienoic acid: A subunit of dolastatin 14. <i>J. Org. Chem.</i> , 62:3332-3339.	

Examiner Signature /John Mabry/ (01/18/2008)	Date Considered
--	-----------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Application No.	10/802,970
	Filing Date	March 16, 2004
	First Named Inventor	Carl-Magnus Andersson
	Art Unit	1624
(Multiple sheets used when necessary)	Examiner	Jason H Johnsen
SHEET 6 OF 8	Attorney Docket No.	ACADIA.014C2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
/J.M./	96	MULLEN et al. 2000. (-)-Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin-2'-one], a conformationally restricted analogue of acetylcholine, is a highly selective full agonist at the $\alpha 7$ nicotinic acetylcholine receptor. <i>J. Med. Chem.</i> , 43:4045-4050.	
	97	MURI, et al. 1998. Synthesis of new benzylic ethers of oximes derived from 1-phenyl-pyrazole compounds. <i>Synthetic Communications</i> , 28(7):1299-1321.	
	98	NG, et al. 1970. L-dopa-induced release of cerebral monoamines. <i>Science</i> , 170:76-77.	
	99	NIGAM, et al. 1957a. Studies with acetylenes. Part II. Some reactions of Grignard reagents with propargylic halides. Model linoleic and linolenic acid systems. <i>J. Chem Soc.</i> , pp. 3868-3873.	
	100	NIGAM, et al. 1957b. The conversion of fatty acids into aldehydes. <i>J. Chem. Soc.</i> , pp.3320-3321.	
	101	NORDSTROM, et al. 1993. High 5-HT <sub>2</sub> receptor occupancy in clozapine treated patients demonstrated by PET. <i>Psychopharmacology</i> , 110:365-367.	
	102	OGAWA, et al. 2005. Effects of R-102444 and its active metabolite R-98544, selective 5-HT <sub>2A</sub> receptor antagonists, on experimental acute and chronic pancreatitis: Additional evidence for possible involvement of 5-HT <sub>2A</sub> receptors in the development of experimental pancreatitis. <i>European Journal of Pharmacology</i> , 521:156-163.	
	103	OLÁH, et al. 1956. Notiz über die N-formylierung von aminen mit formylfluorid. <i>Chem. Ber.</i> , 89:2211-2212.	
	104	OLD, et al. 2002. Efficient palladium-catalyzed N-arylation of indoles. <i>Organic Letters</i> , 2(10):1403-1406.	
	105	PAIVA, et al. 1988. Effects of ritanserine on sleep disturbances of dysthymic patients. <i>Psychopharmacology</i> , 96:395-399.	
	106	PATEL, et al. 2004. The highly selective 5-hydroxytryptamine (5-HT) <sub>2A</sub> receptor antagonist, EMD 281014, significantly increases swimming and decreases immobility in male congenital learned helpless rats in the forced swim test. <i>Synapse</i> , 52:73-75.	
	107	PIERCE, et al. 1995. 5-hydroxytryptamine-induced synovial plasma extravasation is mediated via 5-hydroxytryptamine <sub>2A</sub> receptors on sympathetic efferent terminals. <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 275(1):502-508.	
	108	POLLAK, et al. 1999. Clozapine in drug-induced psychosis in Parkinson's disease. <i>The Lancet</i> , 353:2041-2042.	
	109	READ, W. T. 1922. Researches on hydantoins. Synthesis of the soporific, 4,4-phenylethyl-hydantoin(nirvanol). <i>J. Am. Chem. Soc.</i> , 44:1746-1755.	
	110	RICCI, A. 2000. <i>Modern Animation Methods</i> . New York: Wiley-VCH.	
	111	RICE, et al. 1955. Raney nickel catalyzed N-alkylation of aniline and benzidine with alcohols. <i>J. Am. Chem. Soc.</i> , 77:4052-4054.	
/J.M./	112	RUBIRALTA, M., Giral, E., & Diez, A. 1991. <i>Studies in Organic Chemistry 43. Piperidine: Structure, Preparation, Reactivity and Synthetic Applications of Piperidine and its Derivatives</i> . New York: Elsevier.	

Examiner Signature	/John Mabry/ (01/18/2008)	Date Considered
--------------------	---------------------------	-----------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Application No.	10/802,970
	Filing Date	March 16, 2004
	First Named Inventor	Carl-Magnus Andersson
	Art Unit	1624
(Multiple sheets used when necessary)	Examiner	Jason H Johnsen
SHEET 7 OF 8	Attorney Docket No.	ACADIA.014C2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
/J.M./	113	SADZOT, et al. 1989. Hallucinogenic drug interactions at human brain 5-HT <sub>2</sub> receptors: Implications for treating LSD-induced hallucinogenesis. <i>Psychopharmacology</i> , 98:495-499.	
	114	SCHINS, et al. 2003. Increased coronary events in depressed cardiovascular patients: 5-HT <sub>2A</sub> receptor as missing link? <i>Psychosomatic Medicine</i> , 65:729-737.	
	115	SCRETTAS, et al. 1978. Hydrolithiation of $\alpha$ -olefins by a regiospecific two-step process. Transformation of alkyl phenyl sulfides to alkylolithium reagents. <i>J. Org. Chem.</i> , 43(6):1064-1071.	
	116	SHARPLEY, et al. 1994. Slow wave sleep in humans: Role of 5-HT <sub>2A</sub> and 5-HT <sub>2C</sub> receptors. <i>Neuropharmacology</i> , 33(3/4):467-471.	
	117	STEFANCICH, et al. 1984. Agenti antiinfiammatori non-steroidi: Nota III - sintesi ed attività analgesica-antiinfiammatoria di 4-(pirrol-1-il)-fenilacetamidi e di 4-(pirrol-1-il)fenetilamine. <i>Farmaco Ed. Sci.</i> , 39(9):752-764.	
	118	STRYJER, et al. 2003. Treatment of neuroleptic-induced akathisia with the 5-HT <sub>2A</sub> antagonist trazodone. <i>Clinical Neuropharmacology</i> , 28(3):137-141.	
	119	TSUKAMOTO, et al. 1995. Synthesis and structure-activity studies of a series of 1-oxa-2,8-diazaspiro[4.5]decan-3-ones and related compounds as M <sub>1</sub> muscarinic agonists. <i>Chem. Pharm. Bull.</i> , 43(9):1523-1529.	
	120	VAN LAAR, et al. 2001. Subchronic effects of the GABA-agonist lorazepam and the 5-HT <sub>2A/2C</sub> antagonist ritanserin on driving performance, slow wave sleep and daytime sleepiness in healthy volunteers. <i>Psychopharmacology</i> , 154:189-197.	
	121	VIOLA, et al. 2002. Ritanserin, a serotonin-2 receptor antagonist, improves ultradian sleep rhythmicity in young poor sleepers. <i>Clinical Neurophysiology</i> , 113:429-434.	
	122	VOGEL, A. I. 1948. Physical properties and chemical constitution. Part XIX. Five-membered and six-membered carbon rings. <i>J. Chem. Soc.</i> , pp. 1809-1813.	
	123	VOGL, et al. 2002. Palladium-catalyzed monoarylation of nitroalkanes. <i>J. Org. Chem.</i> , 67(1):106-111.	
	124	WEINER, et al. 2001. 5-Hydroxytryptamine <sub>2A</sub> receptor inverse agonists as antipsychotics. <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 299(1):268-276.	
	125	WHITMORE, et al. 1942. Abnormal Grignard reactions. XII. Sterically hindered aliphatic carbonyl compounds. II. Ketones containing the dineopentylcarbonyl group. <i>J. Am. Chem. Soc.</i> , 64:1247-1251.	
	126	WHITMORE, et al. 1947. Higher hydrocarbons. IV. Six phenyleicosanes and six cyclohexyleicosanes. <i>J. Am. Chem. Soc.</i> , 69:235-237.	
	127	WOLF, V. V. 1952. Über alkin-amine I. Aryl-propargyl-amine. <i>Liebigs Ann. Chem.</i> , 576:35-45.	
	128	WOLFE, et al. 1996. An improved catalyst system for aromatic carbon-nitrogen bond formation: The possible involvement of bis(phosphine) palladium complexes as key intermediates. <i>J. Am. Chem. Soc.</i> , 118:7215-7216.	
/J.M./	129	YAMADA, et al. 1998. Alternative synthesis of TTF donors with a dioxolane ring, and synthesis of their dithiolane and oxathiolane analogues. <i>Tetrahedron Letters</i> , 39:7709-7712.	

Examiner Signature    /John Mabry/ (01/18/2008)	Date Considered
---	-----------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Application No.	10/802,970
	Filing Date	March 16, 2004
	First Named Inventor	Carl-Magnus Andersson
	Art Unit	1624
(Multiple sheets used when necessary)	Examiner	Jason H Johnsen
SHEET 8 OF 8	Attorney Docket No.	ACADIA.014C2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
/J.M./	130	YANG, et al. 1999. Palladium-catalyzed amination of aryl halides and sulfonates. <i>Journal of Organometallic Chemistry</i> , 576:125-146.	
/J.M./	131	YASUHARA, et al. 2000. An activated phosphate for an efficient amide and peptide coupling reagent. <i>J. Chem. Soc., Perkin Trans. 1</i> , 17:2901-2902.	
/J.M./	132	YIN, et al. 2002. Pd-catalyzed intermolecular amidation of aryl halides: The discovery that xantphos can be trans-chelating in a palladium complex. <i>J. Am. Chem. Soc.</i> , 124:6043-6048.	

3490922  
030207

Examiner Signature /John Mabry/ (01/18/2008)	Date Considered
<p><b>*Examiner:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	
<p>T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.</p>	

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Application No.	10/802,970
	Filing Date	March 16, 2004
	First Named Inventor	Carl-Magnus Andersson
	Art Unit	1824
(Multiple sheets used when necessary)	Examiner	Jason H Johnsen
SHEET 1 OF 5	Attorney Docket No.	ACADIA.014C2

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
/J.M./	1	3,983,234	09-28-1976	Sayers	
	2	4,255,432	03-10-1981	Kluge, et al.	
	3	4,332,804	06-01-1982	Clark	
	4	4,353,900	10-12-1982	Clark	
	5	4,353,901	10-12-1982	Clark	
	6	4,367,232	01-04-1983	Boix-Iglesias, et al.	
	7	5,595,872	01-21-1997	Wetterau II, et al.	
	8	5,877,173	03-02-1999	Olney, et al.	
	9	6,911,452	06-28-2005	Schlienger	
	10	7,022,698	04-04-2006	Hamied, et al.	
	11	7,041,667	05-09-2006	Armour, et al.	
	12	7,115,634	10-03-2006	Thurieu, et al.	
	13	2004/0106600 A1	06-03-2004	Andersson, et al.	
	14	2004/0213816 A1	10-28-2004	Weiner, et al.	
	15	2005/0148018 A1	07-07-2005	Weiner, et al.	
	16	2005/0244862 A1	11-03-2005	Brann	
	17	2005/0256108 A1	11-17-2005	Schlienger	
	18	2006/0094758 A1	05-04-2006	Andersson, et al.	
	19	2006/0194778 A1	08-31-2006	Andersson, et al.	
	20	2006/0106063 A1	05-18-2006	Thygesen, et al.	
	21	2006/0111399 A1	05-25-2006	Thygesen, et al.	
	22	2006/0194834 A1	08-31-2006	Andersson, et al.	
	23	2006/0199794 A1	09-07-2006	Schlienger	
	24	2006/0199818 A1	09-07-2006	Andersson, et al.	
	25	2006/0199842 A1	09-07-2006	Weiner, et al.	
	26	2006/0205710 A1	09-14-2006	Schlienger, et al.	
	27	2006/0205722 A1	09-14-2006	Andersson, et al.	
	28	2006/0205780 A1	09-14-2006	Thygesen, et al.	
/J.M./	29	2006/0205781 A1	09-14-2006	Thygesen, et al.	

Examiner Signature	/John Mabry/ (01/18/2008)	Date Considered
--------------------	---------------------------	-----------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Application No.	10/802,970
	Filing Date	March 16, 2004
	First Named Inventor	Carl-Magnus Andersson
	Art Unit	1624
(Multiple sheets used when necessary)	Examiner	Jason H Johnsen
SHEET 2 OF 5	Attorney Docket No.	ACADIA.014C2

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
/J.M./	30	2006/0264465 A1	11-23-2006	Weiner, et al.	
/J.M./	31	2006/0264466 A1	11-23-2006	Weiner, et al.	
/J.M./	32	2006/0286610 A1	12-21-2006	Brann	
/J.M./	33	2006/0292606 A1	12-28-2006	Brann	

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>
/J.M./	34	EP 0 061 333 A1	09-29-1982	Syntex (U.S.A.) Inc.		
	35	HU 157325	03-19-1998	Rudolf, et al.		
	36	WO 97/38665 A2	10-23-1997	Merck & Co., Inc.		
	37	WO 97/38984 A1	10-23-1997	The Dupont Merck Pharmaceutical Company		
	38	WO 98/44921 A1	10-15-1998	Merck & Co., Inc.		
	39	WO 00/59497 A1	10-12-2000	Merck & Co., Inc.		
	40	WO 02/079186 A2	10-10-2002	F. Hoffman-La Roche AG		
	41	WO 03/057898 A2	07-17-2003	Acadia Pharmaceuticals, Inc.		
	42	WO 03/057898 A3	07-17-2003	Acadia Pharmaceuticals, Inc.		
	43	WO 03/062206 A2	07-31-2003	Arena Pharmaceuticals, Inc.		
	44	WO 03/062206 A3	07-31-2003	Arena Pharmaceuticals, Inc.		
	45	WO 03/086400 A1	10-23-2003	Glaxo Group Limited		
	46	WO 2004/000808 A2	12-31-2003	Acadia Pharmaceuticals Inc.		
	47	WO 2004/000808 A3	12-31-2003	Acadia Pharmaceuticals Inc.		
	48	WO 2004/064738 A2	08-05-2004	Acadia Pharmaceuticals Inc.		
	49	WO 2004/064738 A3	08-05-2004	Acadia Pharmaceuticals Inc.		
	50	WO 2004/064753 A2	08-05-2004	Acadia Pharmaceuticals Inc.		
	51	WO 2005/063254 A2	07-14-2005	Acadia Pharmaceuticals Inc.		
	52	WO 2005/112927 A	12-01-2005	Acadia Pharmaceuticals Inc.		
	53	WO 2006/036874 A1	04-06-2006	Acadia Pharmaceuticals Inc.		
/J.M./	54	WO 2006/037043 A1	04-06-2006	Acadia Pharmaceuticals Inc.		

Examiner Signature /John Mabry/ (01/18/2008)	Date Considered
--	-----------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Multiple sheets used when necessary)	Application No.	10/802,970
	Filing Date	March 16, 2004
	First Named Inventor	Carl-Magnus Andersson
	Art Unit	1624
SHEET 3 OF 5	Examiner	Jason H Johnsen
	Attorney Docket No.	ACADIA.014C2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
/J.M./	56	CARON, et al. 1981. Synthesis and antihypertensive activity of a series of 8-substituted 1-Oxa-3,8-diazaspiro[4.5]decan-2-ones. <i>J. Med. Chem.</i> , 24:1320-1328.	
	56	Chemical Abstracts, 73:25305. BENKE, et al. 1970.	
	57	CLIFTON, et al. 1982. Arylethanolamines Derived from Salicyclamide with $\alpha$ - and $\beta$ -Adrenoceptor Blocking Activities. Preparation of Labetalol, its Enantiomers, and Related Salicyclamides. <i>J. Med. Chem.</i> , 25:670-679.	
	58	DELECLUSE, et al. 1998. A case of tardive tremor successfully treated with clozapine. <i>Movement Disorders</i> , 13(5):846-847	
	59	FACTOR, et al. 1992. Clozapine prevents recurrence of psychosis in Parkinson's disease. <i>Movement Disorders</i> , 7(2):125-131.	
	60	FACTOR, et al. 2001. Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: Results of the 12 week open label extension in the PSYCLOPS trial. <i>Movement Disorders</i> , 16(1):135-139.	
	61	FRIEDMAN, J. H. 1994. Clozapine treatment of psychosis in patients with tardive dystonia: Report of three cases. <i>Movement Disorders</i> , 9(3):321-324.	
	62	HARPER, et al. 1984. The chemistry and pharmacology of some 4-aminopiperidines and their derivatives. <i>J. Med. Chem.</i> , 44:729-732.	
	63	HERRICK-DAVIS, et al. 2000. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine <sub>2C</sub> receptors. <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 295(1):226-232.	
	64	MÖHRLE, et al. 1990. Sodium mercury edetate dehydrogenation of N-aliphatic substituted 1,2,3,6-tetrahydropyridine derivatives. <i>Arch. Pharm. (Weinheim)</i> , 323:109-115.	✓ (Abstract)
	65	SMITH, et al. 1995. New spiropiperidines as potent and selective non-peptide tachykinin NK <sub>2</sub> receptor antagonists. <i>J. Med. Chem.</i> , 38(19):3772-3779.	
	66	YOSHIDA, et al. 1998. Marked improvement of tardive dystonia after replacing haloperidol with risperidone in a schizophrenic patient. <i>Clinical Neuropharmacology</i> , 21(1):68-69.	
	67	Notice of Allowance and Fee(s) Due and Notice of Allowability dated May 15, 1997, from Application No. 08/273,669 filed July 12, 1994, now U.S. Pat. No. 5,707,798.	
	68	Office Action dated March 27, 1998, from Application No. 08/954,724 filed October 20, 1997, now U.S. Pat. No. 5,912,132.	
	69	Notice of Allowance and Fee(s) Due and Notice of Allowability dated September 4, 1998, from Application No. 08/954,724 filed October 20, 1997, now U.S. Pat. No. 5,912,132.	
	70	Office Action dated September 14, 1998, from Application No. 08/965,947 filed November 7, 1997, now U.S. Pat. No. 5,955,281.	
/J.M./	71	Interview Summary dated November 17, 1998, from Application No. 08/965,947 filed November 7, 1997, now U.S. Pat. No. 5,955,281.	

Examiner Signature     /John Mabry/ (01/18/2008)	Date Considered
--	-----------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Application No.	10/802,970
	Filing Date	March 16, 2004
	First Named Inventor	Carl-Magnus Andersson
	Art Unit	1624
(Multiple sheets used when necessary)	Examiner	Jason H Johnsen
SHEET 4 OF 5	Attorney Docket No.	ACADIA.014C2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
/J.M./	72	Office Action dated April 25, 2002, from Application No. 09/800,096, now U.S. Pat. No. 6,815,458.	
	73	Office Action dated January 21, 2003, from Application No. 09/800,096, now U.S. Pat. No. 6,815,458.	
	74	Office Action dated July 15, 2003, from Application No. 09/800,096, now U.S. Pat. No. 6,815,458.	
	75	Notice of Allowability dated December 8, 2003, from Application No. 09/800,096 filed March 6, 2001, now U.S. Pat. No. 6,815,458.	
	76	Notice of Allowance and Fee(s) Due and Notice of Allowability dated December 5, 2003, from Application No. 10/409,782 filed April 7, 2003, now U.S. Pat. No. 6,756,393.	
	77	International Preliminary Examination Report dated March 18, 2003, for PCT/US01/07187.	
	78	International Search Report dated July 17, 2001 for PCT/US01/07187.	
	79	Written Opinion dated November 22, 2002 for PCT/US01/07187.	
	80	Office Action dated February 28, 2001, from Application No. 09/413,626 filed October 6, 1999, now U.S. Pat. No. 6,358,698.	
	81	Notice of Allowance and Fee(s) Due and Notice of Allowability dated November 20, 2001, from Application No. 09/413,626 filed October 6, 1999, now U.S. Pat. No. 6,358,698.	
	82	Office Action dated May 21, 2004, from Application No. 10/329,719 filed December 23, 2002, now U.S. Pat. No. 6,911,452.	
	83	Notice of Allowance and Fee(s) Due and Notice of Allowability dated February 11, 2005, from Application No. 10/329,719 filed December 23, 2002, now U.S. Pat. No. 6,911,452.	
	84	Office Action dated January 17, 2006, from Application No. 11/154,083 filed June 16, 2005.	
	85	Office Action dated June 26, 2006, from Application No. 11/154,083 filed June 16, 2005.	
	86	Notice of Allowability, Notice of Allowance and Fee(s) Due, and Interview Summary dated December 15, 2006, from Application No. 11/154,083 filed June 16, 2005.	
	87	Office Action dated October 5, 2006, from Application No. 11/418,322 filed May 3, 2006.	
	88	Office Action dated January 23, 2007, from Application No. 11/418,322 filed May 3, 2006.	
	89	International Search Report dated May 8, 2003 for PCT/US02/41476.	
/J.M./	90	Written Opinion dated September 9, 2003, for PCT/US02/41476.	

Examiner Signature     /John Mabry/ (01/18/2008)	Date Considered
--	-----------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Application No.	10/802,970
	Filing Date	March 16, 2004
	First Named Inventor	Carl-Magnus Andersson
	Art Unit	1824
(Multiple sheets used when necessary)	Examiner	Jason H Johnsen
SHEET 5 OF 5	Attorney Docket No.	ACADIA.014C2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
/J.M./	91	International Preliminary Examination Report dated January 15, 2004, for PCT/US02/41476.	
	92	Office Action dated November 4, 2004, from Application No. 10/601,070 filed June 20, 2003.	
	93	Notice of Allowance and Fee(s) Due and Notice of Allowability dated July 12, 2005, from Application No. 10/601,070 filed June 20, 2003.	
	94	Notice of Allowance and Fee(s) Due and Notice of Allowability dated March 29, 2006, from Application No. 10/601,070 filed June 20, 2003.	
	95	Written Opinion for PCT/US03/19797 dated April 5, 2004.	
	96	International Search Report dated September 8, 2004, for PCT/US2004/001234.	
	97	International Written Opinion dated September 8, 2004, for PCT/US2004/001234.	
	98	International Preliminary Report on Patentability dated April 14, 2005, for PCT/US2004/001234.	
	99	International Search Report dated January 30, 2006, for PCT/US2005/034813	
	100	Written Opinion of the International Searching Authority dated January 30, 2006, for PCT/US2005/034813.	
	101	Written Opinion of the International Searching Authority dated January 30, 2006, for PCT/US2005/034376.	
	102	International Search Report dated January 30, 2006, for PCT/US2005/034376.	
/J.M./	103	Office Action dated February 5, 2007, from Application No. 11/229,566 filed December 12, 2005	

3490889  
030207

Examiner Signature     /John Mabry/ (01/18/2008)	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	
<p>T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.</p>	



# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application No.	10/802970
Filing Date	March 16, 2004
First Named Inventor	Andersson, et al.
Art Unit	1624
Examiner	Johnson, J.
Attorney Docket No.	ACADIA.014C2

(Multiple sheets used when necessary)

SHEET 1 OF 2

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
/J.M./	1	5,707,798	01/13/1998	Brann, Mark	
/J.M./	2	5,216,165	06/01/1993	Mobilio, et al.	
/J.M./	3	2004/0006081 A1	01/08/2004	Burrows, et al.	

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
/J.M./	4	Moulinier, Rev. Neurol. 150: 3-15 (1994). (Abstract)	
	5	Fuller, <i>Biology of Serotonergic Transmission</i> , 1982.	
	6	Boullin, <i>Serotonin In Mental Abnormalities</i> 1: 316 (1978)	
	7	Gershon, et al. <i>The Peripheral Actions of 5-Hydroxytryptamine</i> , 246, (1989)	
	8	Saxena, et al. <i>J. Cardiovascular Pharmacol.</i> 15 supp. 7 (1990)	
	9	Meltzer, <i>Neuropsychopharmacology</i> 21: 106S-115S (1999)	
	10	Barnes & Sharp, <i>Neuropharmacology</i> , 38: 1083-1152 (1999)	
	11	Glennon, <i>Neurosci Biobehavioral Rev.</i> 14:35 (1990)	
	12	Barr & Manning, <i>J. Biol. Chem.</i> 272, 32979-87 (1997)	
	13	Cerione et al., <i>Biochemistry</i> 23: 4519-25 (1984)	
	14	Bond, et al. <i>Nature</i> , 374: 272 (1995)	
	15	Saltzman, et al. <i>Biochem. Biophys. Res. Comm.</i> 181: 1469-1478	
	16	Julius et al. <i>Proc. Natl. Acad. Sci. USA</i> , 87: 928-932.	
/J.M./	17	Pace, et al. <i>Proc. Natl. Acad. Sci. USA</i> , 88: 7031-7035 (1991)	

Examiner Signature /John Mabry/ (01/18/2008)

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Application No.	10/802970
	Filing Date	March 16, 2004
	First Named Inventor	Andersson, et al.
	Art Unit	1624
(Multiple sheets used when necessary)	Examiner	Johnson, J.
SHEET 2 OF 2	Attorney Docket No.	ACADIA.014C2

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
/J.M./	18	Vallar, et al. <i>Nature</i> , 330: 556-558 (1987)	
	19	Eichelbaum, <i>Clin. Exp. Pharmacol. Physio.</i> , 23:983-985 (1996)	
	20	Linder, <i>Clin. Chem.</i> 43: 254-66- (1997)	
	21	Lowe, et al. <i>J. Med. Chem.</i> 37: 2831-40 (1994)	
	22	Carroll, et al., <i>J. Med. Chem.</i> 35: 2184-91 (1992)	
	23	Varma et al., <i>Org. Lett.</i> 1: 697-700 (1999)	
	24	Cherkasov, et al. <i>Tetrahedron</i> 41: 2567 (1985).	
	25	Scheibye, et al. <i>Bull. Soc. Chim. Belg.</i> 87:229 (1978)	
	26	Kuehne et al. <i>J. Org. Chem.</i> 56: 2701 (1991)	
	27	Kuehne, et al. <i>J. Org. Chem.</i> (1991) 56:513	
	28	Mansbach, et al., <i>Psychopharmacology</i> 94 507-514 (1988)	
/J.M./	29	Bakshi, et al., <i>J. Pharmacol. Exp. Ther.</i> 271: 787-94)	

2463622  
032106

Examiner Signature	/John Mabry/ (01/18/2008)	Date Considered
--------------------	---------------------------	-----------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Multiple sheets used when necessary)

SHEET 1 OF 1

Application No.	10/802,970
Filing Date	March 16, 2004
First Named Inventor	Andersson, et al.
Art Unit	1614
Examiner	Johnson, J.H.
Attorney Docket No.	ACADIA.014C2

**U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
/J.M./	1	2005-0014757-a1	06-20-05	Andersson, et al.	
/J.M./	2	6,815,458	11-09-04	Andersson, et al.	
/J.M./	3	6,756,393	06-29-04	Andersson, et al.	
/J.M./	4	2004-0006089 A1	01-08-04	Christophe, et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>
/J.M./	5	WO 01/66521 A1	09-13-2001	Andersson, et al.		
/J.M./	6	2 802 206	06/15/2001	Christophe, et al.		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
/J.M./	7	KALGUTKAR, et al. <i>Selective Inhibitors of Monoamine Oxidase (MAO-A and MAO-B) as Probes of its Catalytic</i> , XP002034298, Medicinal Research Reviews, Vol. 15, No. 4, 325-388 (1988).	
/J.M./	8	International Search Report for corresponding PCT Application No. PCT/US03/19797.	
/J.M./	9	International Preliminary Examination Report for corresponding PCT Application No. PCT/US03/19797.	


2299247  
011706

Examiner Signature /John Mabry/ (01/18/2008)

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

 FORM PTO-449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. ACADIA.014C2		APPLICATION NO. 10/802,970	
	APPLICANT Andersson et al.			
	FILING DATE March 16, 2004		GROUP Unknown	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
/J.M./	1	4,853,394	08/01/89	King, et al.			
/J.M./	2	5,216,165	06/01/93	Mobilio, et al.			

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
/J.M./	3	0 260 070	03/16/88	EPO				
/J.M./	4	0 625 507	07/23/97	EPO				
/J.M./	5	9,738,984	10/1997	WO				
/J.M./	6	WO 00/23076	04/27/00	PCT				
/J.M./	7	WO 01/44191	06/21/01	PCT				
/J.M./	8	WO 01/87839	11/22/01	PCT				
/J.M./	9	WO 94/27967	12/08/94	PCT				
/J.M./	10	WO 98/50534	11/12/98	PCT				

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
/J.M./	11	Wade, et al., Application of Base Cleavable Safety Catch Linkers to Solid Phase Library Production, J. Comb. Chem. 2:266-275 (2000)

S:\DOCS\SKT\SKT-5139.DOC  
061604

x Did not receive any FOR.

EXAMINER /John Mabry/ (01/18/2008)	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	